RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA
Clinical trials for RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo aims to outsmart recurrent ovarian cancer
Disease control OngoingThis study tests whether adding an immunotherapy drug (tremelimumab) to a standard targeted therapy (olaparib) can better control recurrent ovarian, fallopian tube, or peritoneal cancer that still responds to platinum chemotherapy. About 61 adults with these cancers will receive …
Matched conditions: RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:16 UTC
-
New hope for recurrent ovarian and endometrial cancers: targeted drug shows promise
Disease control OngoingThis study tests a drug called tazemetostat in people whose ovarian or endometrial cancer has returned after previous treatment. The drug works by blocking a protein that helps cancer cells grow. The goal is to see if it can shrink tumors or slow the disease. About 62 participant…
Matched conditions: RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:58 UTC
-
New hope for hard-to-treat ovarian cancer: three-drug showdown
Disease control OngoingThis study compares three different combinations of chemotherapy and targeted drugs in 444 women with ovarian, fallopian tube, or peritoneal cancer that came back and no longer responds to platinum-based chemotherapy. The goal is to find which combination best delays cancer growt…
Matched conditions: RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New drug combo could offer alternative to chemo for recurrent ovarian cancer
Disease control OngoingThis phase 3 study tested whether the targeted drugs olaparib (alone or combined with cediranib) work better than standard platinum-based chemotherapy for women with ovarian, fallopian tube, or primary peritoneal cancer that came back after initial treatment. About 579 women with…
Matched conditions: RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New hope for ovarian cancer: drug combo targets resistant tumors
Disease control OngoingThis early-phase trial tests a new drug (peposertib) combined with standard chemotherapy (PLD) in people with ovarian or related cancers that no longer respond to platinum-based treatment. The goal is to find the safest dose and see if the combo can shrink tumors or slow their gr…
Matched conditions: RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
New drug cocktail shows promise for Tough-to-Treat ovarian cancer
Disease control OngoingThis study tests whether combining three drugs (durvalumab, olaparib, and cediranib) works better than standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatment. About 120 participants will receive o…
Matched conditions: RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 18, 2026 12:12 UTC